Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01685411 · ClinicalTrials.gov registry record · NA
Busulfan and Cyclophosphamide Followed By ALLO BMT
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT01685411 is a NA study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 5 participants.
The verdict
NCT01685411, a NA study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a treatment guideline to allow routine clinical data to be collected and maintained in Oncore (clinical database) and the University of Minnesota Blood and Marrow Database as part of the historical database maintained by the department.
Interventions
- DRUG Cyclophosphamide
- DRUG Busulfan
- DRUG Allopurinol
- DRUG Tacrolimus
- DRUG Keppra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2013-01 |
| Est. Completion | 2020-02-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01685411
The ClinicalTrials.gov registry entry for NCT01685411 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01685411 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01685411 about?
NCT01685411 is a clinical study titled "Busulfan and Cyclophosphamide Followed By ALLO BMT". This is a treatment guideline to allow routine clinical data to be collected and maintained in Oncore (clinical database) and the University of Minnesota Blood and Marrow Database as part of the historical database maintained by the department.
What is the current status of trial NCT01685411?
This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2013-01. Estimated completion is 2020-02-10.
What interventions are being tested in trial NCT01685411?
The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), Allopurinol (DRUG), Tacrolimus (DRUG), Keppra (DRUG).
Who is sponsoring clinical trial NCT01685411?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.